PTGX
Protagonist Therapeutics Inc
139.90$
-0.7%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | 1.4% | 0.3% | 21.4% | – | 0.4% | – | – | – | 5.1% | 0.7% | – | – | |
| – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 99.3% | 100.0% | 99.9% | |
| – | 48.2% | 13.2% | 804.4% | 769.4% | 20.5% | 126.7% | 667.8% | 849.0% | 623.3% | 82.9% | 19.7% | 62.1% | |
| – | 13.4% | 5.8% | 226.5% | 217.3% | 5.2% | 41.4% | 190.2% | 236.2% | 153.7% | 23.6% | 5.9% | 17.2% | |
| – | 61.6% | 19.1% | 1,031.0% | 986.7% | 25.7% | 168.2% | 858.0% | 1,085.2% | 777.1% | 105.7% | 25.6% | 79.2% | |
| – | 38.4% | 80.9% | -931.0% | -886.7% | 74.3% | -68.2% | -758.0% | -985.2% | -677.1% | -6.5% | 74.4% | 20.7% | |
| – | 3.8% | – | – | – | – | – | – | – | – | – | – | – | |
| – | 45.6% | 82.6% | -750.9% | -719.4% | 78.3% | -41.2% | -623.9% | -834.9% | -587.8% | 4.0% | 77.3% | 29.9% | |
| – | -7.1% | 1.3% | -16.2% | -9.0% | 1.2% | – | 3.1% | – | 9.0% | -2.7% | 1.1% | – | |
| – | 45.6% | 81.3% | -734.7% | -710.4% | 77.2% | -41.2% | -627.0% | -834.9% | -596.8% | 6.7% | 76.3% | 29.4% | |
| – | 46.9% | 82.7% | -715.5% | -705.5% | 78.6% | -40.3% | -618.4% | -827.2% | -582.8% | 4.8% | 77.5% | 30.5% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.